X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-bid-revive-cholesterol-drug-patents-comes-us-supreme-court-2023-03-27/
https://www.reuters.com/legal/amgen-sanofi-patent-case-divides-makers-antibody-drugs-2023-03-27/
https://www.fiercepharma.com/pharma/scotus-decision-looms-amgen-attacks-sanofis-contrary-claims-divisive-repatha-patent-fight
https://www.prnewswire.com/news-releases/amgen-to-present-new-repatha-evolocumab-and-olpasiran-data-at-acc-301759141.html
https://endpts.com/philip-tagari-switches-amgens-discovery-lab-for-insitros-machine-learning-tools-ceo-joaquin-duato-to-chair-jjs-board/
https://www.fiercepharma.com/pharma/amgens-supreme-court-hail-mary-answered-long-running-repatha-patent-feud-sanofi-regeneron
https://www.prnewswire.com/news-releases/new-amgen-data-at-esc-2022-show-long-term-ldl-c-lowering-with-repatha-evolocumab-was-well-tolerated-for-more-than-8-years-301613524.html
https://endpts.com/amgen-touts-its-latest-cut-of-longterm-repatha-data-still-hunting-elusive-billions-for-pcsk9-franchise/
https://endpts.com/supreme-court-calls-on-top-government-lawyer-to-weigh-pcsk9-patent-appeal/
https://www.fiercepharma.com/pharma/repatha-patent-feud-supreme-court-summons-big-guns-weigh-amgens-appeal
https://seekingalpha.com/news/3801302-innovent-biologics-cholesterol-drug-ibi306-meets-main-goal-in-2-studies
https://www.fiercepharma.com/pharma/amgen-takes-high-profile-pcsk9-patent-fight-sanofi-and-regeneron-to-supreme-court
https://www.fiercepharma.com/pharma/amgen-s-otezla-repatha-and-biosimilars-put-notice-challenging-years-ahead
https://www.biospace.com/article/merck-s-anti-cholesterol-drug-threatens-esperion-and-other-pcsk9-inhibitor-makers/?s=71
https://finance.yahoo.com/finance/news/esperion-chops-40-workforce-launch-215424232.html
https://www.fiercepharma.com/pharma/fda-approval-for-pediatric-patients-hehf-cholesterol-condition-amgen-s-repatha-solidifies
https://www.prnewswire.com/news-releases/fda-approves-repatha-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolemia-301385035.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522
https://www.prnewswire.com/news-releases/new-data-at-esc-congress-2021-shows-repatha-evolocumab-improves-features-of-plaque-stability-in-patients-with-acute-coronary-syndrome-acs-301364057.html
https://www.bigmoleculewatch.com/2021/06/08/sanofi-files-opposition-to-amgens-petition-for-federal-circuit-to-reconsider-decision-invalidating-praluent-patents/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+goodwinprocter-bigmoleculewatchblog+%28Big+Molecule+Watch+Blog+%7C+Goodwin%29
https://www.reuters.com/article/ip-amgen/amgen-loses-bid-to-revive-patents-for-cholesterol-drug-repatha-idUSL1N2KH3EZ
https://www.fiercepharma.com/pharma/esc-amgen-chases-pediatric-use-for-cholesterol-busting-pcsk9-med-repatha
https://www.fiercepharma.com/pharma/esc-amgen-chases-pediatric-use-for-cholesterol-busting-pcsk9-med-repatha
https://www.prnewswire.com/news-releases/amgen-announces-positive-data-from-phase-3b-study-of-repatha-evolocumab-in-pediatric-patients-with-heterozygous-familial-hypercholesterolemia-at-esc-congress-2020-301120643.html
https://www.prnewswire.com/news-releases/new-amgen-data-to-be-presented-at-esc-congress-2020-highlighting-repatha-evolocumab-efficacy-in-high-risk-patient-populations-301118228.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522
https://www.prnewswire.com/news-releases/amgen-announces-positive-results-at-acc20wcc-from-phase-3b-study-of-repatha-evolocumab-in-people-living-with-hiv-who-have-high-ldl-cholesterol-301031307.html
https://www.fiercepharma.com/pharma/aha-amgen-s-repatha-tied-to-higher-risk-reduction-high-risk-heart-attack-patients
https://www.prnewswire.com/news-releases/amgen-announces-new-fourier-analysis-showing-benefit-of-repatha-evolocumab-in-high-risk-patients-who-have-experienced-a-recent-heart-attack-300959550.html
https://www.pharmaceutical-technology.com/news/amgen-low-price-repatha-supply/
https://endpts.com/medco-builds-its-case-for-star-cholesterol-rnai-therapy-with-two-new-positive-pivotal-studies/
https://www.biospace.com/article/u-s-district-court-invalidates-amgen-patents-over-cholesterol-med/
https://www.biopharmadive.com/news/amgen-patents-on-repatha-invalid-judge-rules-in-reversal/561882/
https://www.biopharmadive.com/news/medicines-company-inclisiran-orion-11-pcsk9-ldl-cholesterol/561667/
https://www.fiercepharma.com/marketing/amgen-s-sanofi-s-already-lackluster-pcsk9-drugs-could-be-under-major-threat-analyst
https://pharmaphorum.com/news/evinacumab-regeneron-cholesterol-drug-trial/
https://www.cnbc.com/2019/08/14/novartis-allegedly-fires-brother-scientists-over-data-manipulation.html
https://www.fiercepharma.com/pharma/novartis-avexis-shifted-top-scientific-leadership-before-zolgensma-data-scandal-erupted
https://endpts.com/armed-with-stellar-if-niche-phiii-data-regeneron-steers-breakthrough-cholesterol-drug-to-post-pcsk9-waters/
https://www.fiercepharma.com/pharma/amgen-scores-repatha-patent-win-germany-over-pcsk9-rivals-sanofi-regeneron
https://www.fiercepharma.com/marketing/wifi-targeted-campaigns-head-to-doctor-s-office-to-reach-waiting-patients-their?utm_source=internal&utm_medium=rss
https://www.fiercebiotech.com/biotech/long-term-data-med-co-alnylam-s-cholesterol-fighter-inclisiran-poised-for-2019-filing
https://www.fiercepharma.com/pharma/key-drugs-repatha-aimovig-flail-as-cheap-copies-eat-into-amgen-sales
https://endpts.com/as-praluent-q1-sales-miss-wall-street-expectations-fda-expands-drugs-label-to-reflect-cv-risk-reduction/
https://www.fiercepharma.com/pharma/sanofi-regeneron-hope-to-boost-praluent-uptake-new-cv-nod
https://www.fiercepharma.com/marketing/amgen-debuts-new-toned-down-tv-ad-for-repatha-70s-disco-music-and-wedding-revelry
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522
https://www.fiercepharma.com/marketing/amgen-glaxosmithkline-boehringer-brands-snag-quarterfinal-spots-fiercemadness-dtc
https://www.forbes.com/sites/johnlamattina/2019/03/27/outcomes-based-pricing-not-a-panacea-for-high-priced-drugs/#68d188035c23
http://www.pmlive.com/pharma_news/sanofi_gets_cardio_outcomes_claim_for_praluent_in_eu_1281850
Market Place
Share 
